Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells

被引:6
|
作者
Klaihmon, Phatchanat [1 ]
Luanpitpong, Sudjit [1 ,2 ]
Kang, Xing [1 ]
Issaragrisil, Surapol [1 ,3 ,4 ]
机构
[1] Mahidol Univ, Siriraj Hosp, Fac Med, Siriraj Ctr Excellence Stem Cell Res, Bangkok, Thailand
[2] Mahidol Univ, Fac Med, Blood Prod & Cellular Immunotherapy Res Grp, Siriraj Hosp, Bangkok, Thailand
[3] Mahidol Univ, Fac Med, Siriraj Hosp 2, Dept Med,Siriraj Hosp,Div Hematol, Bangkok 10700, Thailand
[4] Wattanosoth Canc Hosp, BDMS Ctr Excellence Hematol, Bangkok, Thailand
关键词
Induced pluripotent stem cells; Natural killer cells; Chimeric antigen receptor; CAR; TIM3; Acute myelogenous leukemia; Immunotherapy; T-CELLS; TRANSPLANTATION; CANCER; TIM-3; EXPRESSION; HIERARCHY; EXPANSION;
D O I
10.1186/s12935-023-03153-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundAcute myeloid leukemia (AML) is a clonal malignant disorder which originates from a small number of leukemia-initiating cells or leukemic stem cells (LSCs)-the subpopulation that is also the root cause of relapsed/refractory AML. Chimeric antigen receptor (CAR)-T cell therapy has proved successful at combating certain hematologic malignancies, but has several hurdles that limit its widespread applications. CAR-natural killer (NK) cells do not carry the risk of inducing graft-versus-host disease (GvHD) frequently associated with allogeneic T cells, thereby overcoming time-consuming, autologous cell manufacturing, and have relatively safer clinical profiles than CAR-T cells. The present study aimed to generate anti-TIM3 CAR-NK cells targeting LSCs from a clonal master induced pluripotent stem cells engineered with the third-generation anti-TIM3 CAR.MethodsA clonal master umbilical cord blood NK-derived induced pluripotent stem cell (iPSC) line, MUSIi013-A, was used as a starting cells for engineering of an anti-TIM3 CAR harboring TIM3 scFv fragment (clone TSR-022), CD28, 4-1BB, and CD3 zeta signaling (CAR-TIM3). The established CAR-TIM3 iPSCs were further differentiated under serum- and feeder-free conditions into functional CAR-TIM3 NK cells and tested for its anti-tumor activity against various TIM3-positive AML cells.ResultsWe successfully established a single-cell clone of CAR-TIM3 iPSCs, as validated by genomic DNA sequencing as well as antibody and antigen-specific detection. We performed thorough iPSC characterization to confirm its retained pluripotency and differentiation capacity. The established CAR-TIM3 iPSCs can be differentiated into CAR-TIM3 NK-like cells, which were further proven to have enhanced anti-tumor activity against TIM3-positive AML cells with minimal effect on TIM3-negative cells when compared with wild-type (WT) NK-like cells from parental iPSCs.ConclusionsiPSCs engineered with CARs, including the established single-cell clone CAR-TIM3 iPSCs herein, are potential alternative cell source for generating off-the-shelf CAR-NK cells as well as other CAR-immune cells. The feasibility of differentiation of functional CAR-TIM3 NK cells under serum- and feeder-free conditions support that Good Manufacturing Practice (GMP)-compliant protocols can be further established for future clinical applications.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] SPECIFIC TARGETING OF ACUTE MYELOID LEUKEMIA BY THE USE OF ENGINEERED CIK (CYTOKINE-INDUCED KILLER) CELLS EXPRESSING THE ANTI-CD33 CHIMERIC ANTIGEN RECEPTOR (CAR)
    Rotiroti, M. C.
    Arcangeli, S.
    Magnani, C. F.
    Cappuzzello, C.
    Biondi, A.
    Tettamanti, S.
    Biagi, E.
    HAEMATOLOGICA, 2016, 101 : S42 - S42
  • [32] SPECIFIC TARGETING OF ACUTE MYELOID LEUKEMIA BY THE USE OF ENGINEERED CIK (CYTOKINE-INDUCED KILLER) CELLS EXPRESSING THE ANTI-CD33 CHIMERIC ANTIGEN RECEPTOR (CAR)
    Rotiroti, M. C.
    Arcangeli, S.
    Magnani, C. F.
    Cappuzzello, C.
    Biondi, A.
    Tettamanti, S.
    Biagi, E.
    HAEMATOLOGICA, 2017, 102 : 247 - 248
  • [33] Specific Targeting of Acute Myeloid Leukemia by the use of Engineered CIK (Cytokine-Induced Killer) Cells Expressing the Anti-CD33 Chimeric Antigen Receptor (CAR)
    Rotiroti, M. C.
    Arcangeli, S.
    Magnani, C. F.
    Cappuzzello, C.
    Biondi, A.
    Tettamanti, S.
    Biagi, E.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S54 - S55
  • [34] TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells
    Kikushige, Yoshikane
    Shima, Takahiro
    Takayanagi, Shin-ichiro
    Urata, Shingo
    Miyamoto, Toshihiro
    Iwasaki, Hiromi
    Takenaka, Katsuto
    Teshima, Takanori
    Tanaka, Toshiyuki
    Inagaki, Yoshimasa
    Akashi, Koichi
    CELL STEM CELL, 2010, 7 (06) : 708 - 717
  • [35] Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy
    Chaudhry, Kajal
    Dowlati, Ehsan
    Bollard, Catherine M.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2021, 17 (06) : 643 - 659
  • [36] PRDM1 knockout chimeric antigen receptor-natural killer cells exhibit durable anti-tumor efficacy
    Nakashima, Takahiro
    Yoshikawa, Toshiaki
    Matsukawa, Tetsuya
    Ito, Yusuke
    Inoue, Satoshi
    Iida, Shinsuke
    Kagoya, Yuki
    CANCER SCIENCE, 2025, 116 : 98 - 98
  • [37] Combinatorial chimeric antigen receptor T cells for the treatment of acute myeloid leukemia
    Mueller, J.
    Myburgh, R.
    Manz, M. G.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 39 - 39
  • [38] Chimeric-antigen receptor engineered human T lymphocytes from induced pluripotent stem cells for cancer therapy.
    Themeli, Maria
    Sadelain, Michel
    JOURNAL OF IMMUNOLOGY, 2014, 192
  • [39] Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy
    Cai Zhang
    Yuan Hu
    Weihua Xiao
    Zhigang Tian
    Cellular & Molecular Immunology, 2021, 18 : 2083 - 2100
  • [40] Expression of Tim-3 on natural killer cells in patients with acute myeloid leukemia and its clinical significance
    马金凤
    China Medical Abstracts(Internal Medicine), 2019, 36 (04) : 228 - 229